BioPharmSignal logoBioPharmSignal

Biotech News

Delcath Systems to Host Fourth Quarter and Full Year 2025 Earnings Call

Delcath Systems (DCTH)Delcath SystemsEarnings

QUEENSBURY, N.Y. --(BUSINESS WIRE)--Feb. 12, 2026-- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on February 26, 2026, at 8:30 AM Eastern Time to

Related news

DCTHDelcath Systems2026-07-23 20:01 EST

Delcath Systems to Host Second Quarter 2026 Earnings Call

DCTHDelcath Systems2026-08-06 12:01 EST

Delcath Systems Reports Second Quarter 2026 Results and Business Highlights

SNDXSyndax Pharmaceuticals2026-07-28 11:00 EST

Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026

ICUIICU Medical2026-07-23 12:30 EST

ICU Medical Announces Time of Second Quarter 2026 Earnings Conference Call

EHCEncompass Health Corporation2026-07-09 20:30 EST

Encompass Health announces date of 2026 second quarter earnings call

REGNRegeneron Pharmaceuticals2026-06-25 20:05 EST

Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast

ACHCAcadia Healthcare2026-07-28 20:05 EST

Acadia Healthcare Announces Second Quarter 2026 Results and Updates Full Year 2026 Financial and Cash Flow Guidance

SHCSotera Health2026-07-23 11:00 EST

Sotera Health Announces Second-Quarter 2026 Earnings Release Date

IARTIntegra LifeSciences2026-07-16 12:00 EST

Integra LifeSciences to Host Second Quarter 2026 Financial Results Conference Call on July 29, 2026

ACHCAcadia Healthcare2026-07-09 20:15 EST

Acadia Healthcare Announces Date for Second Quarter 2026 Earnings Release

View all latest news

Delcath Systems

Interventional Oncology Delcath Systems develops liver-directed therapies for primary and metastatic liver cancers. Its technology isolates hepatic circulation so high-dose chemotherapy can be delivered to the liver while limiting systemic exposure. HEPZATO KIT HEPZATO KIT combines melphalan with the company's percutaneous...

Recent company news

DCTHDelcath Systems2026-08-06 12:01 EST

Delcath Systems Reports Second Quarter 2026 Results and Business Highlights

DCTHDelcath Systems2026-07-28 20:01 EST

Delcath Systems to Participate at the Canaccord Genuity 46th Annual Growth Conference

DCTHDelcath Systems2026-07-23 20:01 EST

Delcath Systems to Host Second Quarter 2026 Earnings Call

DCTHDelcath Systems2026-07-16 20:01 EST

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DCTHDelcath Systems2026-07-09 12:00 EST

Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer

Stock data

Close
17.14 USD
Market cap
363.51M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States